Most cited papers from Zymenex (Denmark)

Zymenex (Denmark)

What are the most cited papers from Zymenex (Denmark)?

The most cited paper from Zymenex (Denmark) is "Enzyme replacement improves nervous system pathology and function in a mouse model for metachromatic leukodystrophy" (Ulrich Matzner, Eva M. Herbst, Kerstin Khalaj Hedayati et al., 2005), with 149 citations. Next come "Natural history of alpha mannosidosis a longitudinal study" (74) and "Variations in Porphobilinogen and 5-Aminolevulinic Acid Concentrations in Plasma and Urine from Asymptomatic Carriers of the Acute Intermittent Porphyria Gene with Increased Porphyrin Precursor Excretion" (67).

Published FieldAccess

Showing 29 of 29 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Enzyme replacement improves nervous system pathology and function in a mouse model for metachromatic leukodystrophy Ulrich Matzner, Eva M. Herbst, Kerstin Khalaj Hedayati et al. · Human Molecular Genetics	16 Mar 2005	149
2	Natural history of alpha mannosidosis a longitudinal study Michael Beck, Klaus J Olsen, James Edmond Wraith et al. · Orphanet Journal of Rare Diseases Open access	2013	74
3	Variations in Porphobilinogen and 5-Aminolevulinic Acid Concentrations in Plasma and Urine from Asymptomatic Carriers of the Acute Intermittent Porphyria Gene with Increased Porphyrin Precursor Excretion Ylva Flodérus, Eliane Sardh, Christer Möller et al. · Clinical Chemistry	24 Feb 2006	67
4	Reversal of peripheral and central neural storage and ataxia after recombinant enzyme replacement therapy in α-mannosidosis mice Judith Blanz, Stijn Stroobants, Renate Lüllmann‐Rauch et al. · Human Molecular Genetics	19 Aug 2008	66
5	Enzyme Replacement Improves Ataxic Gait and Central Nervous System Histopathology in a Mouse Model of Metachromatic Leukodystrophy Ulrich Matzner, Renate Lüllmann‐Rauch, Stijn Stroobants et al. · Molecular Therapy Open access	27 Jan 2009	66
6	Efficacy and safety of Velmanase alfa in the treatment of patients with alpha‐mannosidosis: results from the core and extension phase analysis of a phase III multicentre, double‐blind, randomised, placebo‐controlled trial Line Gutte Borgwardt, Nathalie Guffon, Yasmina Amraoui et al. · Journal of Inherited Metabolic Disease Open access	30 May 2018	65
7	Alpha-mannosidosis: correlation between phenotype, genotype and mutant MAN2B1 subcellular localisation Line Gutte Borgwardt, Hilde Monica Frostad Riise Stensland, Klaus J Olsen et al. · Orphanet Journal of Rare Diseases Open access	5 Jun 2015	61
8	Comprehensive long‐term efficacy and safety of recombinant human alpha‐mannosidase (velmanase alfa) treatment in patients with alpha‐mannosidosis Allan Meldgaard Lund et al. · Journal of Inherited Metabolic Disease Open access	3 May 2018	58
9	Intracerebroventricular enzyme infusion corrects central nervous system pathology and dysfunction in a mouse model of metachromatic leukodystrophy Stijn Stroobants, D. Gerlach, Frank Matthes et al. · Human Molecular Genetics	22 Apr 2011	58
10	Efficacy of enzyme replacement therapy in an aggravated mouse model of metachromatic leukodystrophy declines with age Frank Matthes, Stijn Stroobants, D. Gerlach et al. · Human Molecular Genetics Open access	2 Mar 2012	53
11	Enzyme replacement therapy for alpha‐mannosidosis: 12 months follow‐up of a single centre, randomised, multiple dose study Lise Borgwardt et al. · Journal of Inherited Metabolic Disease	13 Mar 2013	45
12	Safety, Pharmacokinetics and Pharmocodynamics of Recombinant Human Porphobilinogen Deaminase in Healthy Subjects and Asymptomatic Carriers of the Acute Intermittent Porphyria Gene Who Have Increased Porphyrin Precursor Excretion Eliane Sardh, Lillan Rejkj r, Dan Andersson et al. · Clinical Pharmacokinetics	2007	44
13	Enzyme replacement therapy of a novel humanized mouse model of globoid cell leukodystrophy Frank Matthes, Claes R. Andersson, Axel Stein et al. · Experimental Neurology	6 May 2015	39
14	Non-inhibitory antibodies impede lysosomal storage reduction during enzyme replacement therapy of a lysosomal storage disease Ulrich Matzner, Frank Matthes, Cecilia Weigelt et al. · Journal of Molecular Medicine	17 Mar 2008	35
15	Site-specific analysis of N-linked oligosaccharides of recombinant lysosomal arylsulfatase A produced in different cell lines Stephan Schröder, Frank Matthes, Pia Hydén et al. · Glycobiology	28 Oct 2009	26
16	Cerebellar Alterations and Gait Defects as Therapeutic Outcome Measures for Enzyme Replacement Therapy in α-Mannosidosis Markus Damme, Stijn Stroobants, Steven U. Walkley et al. · Journal of Neuropathology & Experimental Neurology Open access	11 Dec 2010	26
17	Induction of Tolerance to Human Arylsulfatase A in a Mouse Model of Metachromatic Leukodystrophy Ulrich Matzner, Frank Matthes, Eva M. Herbst et al. · Molecular Medicine Open access	Sep 2007	25
18	Transport of Arylsulfatase A across the Blood-Brain Barrier in Vitro Frank Matthes, Philipp Wölte, Annika Böckenhoff et al. · Journal of Biological Chemistry Open access	29 Mar 2011	25
19	Impaired Lysosomal Trimming of N-Linked Oligosaccharides Leads to Hyperglycosylation of Native Lysosomal Proteins in Mice with α-Mannosidosis Markus Daμμe, Willy Morelle, Bernhard F. Schmidt et al. · Molecular and Cellular Biology Open access	3 Nov 2009	21
20	Cognitive profile and activities of daily living: 35 patients with alpha‐mannosidosis Lise Borgwardt, A. M. Thuesen, K. J. Olsen et al. · Journal of Inherited Metabolic Disease	27 May 2015	20
21	Determination of amitriptyline-n-oxide, amitriptyline and nortriptyline in serum and plasma by high-performance liquid chromatography Karen Møller Jensen · Journal of Chromatography B Biomedical Sciences and Applications	Sep 1980	17
22	Alpha‐mannosidosis: characterization of CNS pathology and correlation between CNS pathology and cognitive function Lise Borgwardt, Else Rubæk Danielsen, Cecilie Dubgaard Thomsen et al. · Clinical Genetics	23 Jul 2015	16
23	Long-term enzyme replacement therapy improves neurocognitive functioning and hippocampal synaptic plasticity in immune-tolerant alpha-mannosidosis mice Stijn Stroobants, Markus Daμμe, Ann Van der Jeugd et al. · Neurobiology of Disease Open access	15 Jul 2017	12
24	Chronic enzyme replacement therapy ameliorates neuropathology in alpha‐mannosidosis mice Markus Daμμe, Stijn Stroobants, Meike Lüdemann et al. · Annals of Clinical and Translational Neurology Open access	19 Sep 2015	8
25	Long-term enzyme replacement therapy with velmanase alfa (human recombinant alpha-mannosidase) slows disease progression in adult patients suffering from alpha-mannosidosis Line Gutte Borgwardt et al. · Molecular Genetics and Metabolism	2017	5
26	Improvement in fine and gross motor proficiency after long-term enzyme replacement therapy with velmanase alfa (human recombinant alpha mannosidase) in alpha-mannosidosis patients Line Gutte Borgwardt et al. · Molecular Genetics and Metabolism	2017	3
27	Enzyme Replacement Therapy for Patients with Alpha-Mannosidosis Line Gutte Borgwardt, Christine í Dali, Jens M. Fogh et al. · Molecular Genetics and Metabolism	20 Jan 2012	2
28	Long-term enzyme replacement therapy with velmanase alfa (human recombinant alpha-mannosidase) improves mobility in alpha-mannosidosis patients Allan Meldgaard Lund et al. · Molecular Genetics and Metabolism	2017	1
29	Improvement in pulmonary function and serum immunoglobulin G in long-term enzyme replacement therapy with velmanase alfa(human recombinant alpha-mannosidase) in alpha-mannosidosis patients Line Gutte Borgwardt et al. · Molecular Genetics and Metabolism	2017	0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.